Myocholine (Bethanechol Chloride)

Bethanechol directly stimulates muscarinic (M3) receptors on smooth‑muscle cells of the bladder and gastrointestinal tract. This activation triggers a G‑protein cascade that raises intracellular calcium levels, leading to muscle contraction, improved bladder emptying, and accelerated intestinal peristalsis.

The dose of Myocholine is individualized by the prescribing clinician based on the patient’s condition, severity, and response. Healthcare providers determine the appropriate strength, frequency, and duration of therapy in accordance with local prescribing guidelines.

Safety data for bethanechol during pregnancy and lactation are limited. The drug should only be used when the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Myocholine, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

The primary alternative to bethanechol is neostigmine, another cholinergic agent. While both increase smooth‑muscle activity, bethanechol is a direct muscarinic agonist with minimal nicotinic activity, offering more selective bladder and gastrointestinal effects and a lower risk of neuromuscular side effects compared with neostigmine.

Myocholine should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight, and excessive heat to maintain potency and stability.

Myocholine is administered orally. The tablet should be swallowed whole with a glass of water and can be taken with or without food, unless the prescribing clinician advises otherwise.

Serious adverse events include bronchospasm, severe hypotension, cardiac arrhythmias, and cholinergic crisis characterized by muscle weakness, respiratory depression, and excessive salivation. Patients should seek immediate medical attention if they experience difficulty breathing, fainting, or rapid heart rate changes.

Myocholine is contraindicated in individuals with mechanical urinary obstruction (e.g., bladder stones or strictures), known hypersensitivity to bethanechol, severe asthma or COPD, recent myocardial infarction, and in patients where cholinergic stimulation could worsen their condition. A healthcare professional must evaluate suitability before prescribing.